WIZP - Wize Pharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.6769
+0.0870 (+14.75%)
As of 10:18AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.5899
Open0.7399
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6769 - 0.7500
52 Week Range0.2800 - 6.1000
Volume2,501
Avg. Volume42,190
Market Cap6.713M
Beta (3Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.4680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Wize Pharma Issues Letter to Shareholders
    PR Newswireyesterday

    Wize Pharma Issues Letter to Shareholders

    HOD HASHARON, Israel, May 21, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today issued a Letter to Shareholder. Concurrently, I increased my stake in the company through a $400,000 investment at a price of about $1.00 per share.

  • Zacks Small Cap Research2 days ago

    WIZP: Performing according to plan

    By Beth Senko, CFA OTC:WIZP READ THE FULL WIZP RESEARCH REPORT On May 15, Wize Pharma Inc. (OTC:WIZP) posted first quarter results in line with expectations. Net income improved to $0.15 million from a ...

  • Zacks Small Cap Research15 days ago

    WIZP: Initiating coverage – a better treatment for dry eye

    Wize Pharma, Inc. (WIZP) is seeking FDA approval for LO2A, a proprietary formulation of artificial tears for the treatment of Sjögren’s and conjunctivochalasis (CCH) in dry eye syndrome. While the competitive landscape is significant, we believe the company will carve out a modest share of the US market based on LO2A’s approval for DES, Sjögren’s and CCH in four European nations if it receives FDA approval.

  • Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City
    PR Newswire22 days ago

    Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City

    HOD HASHARON, Israel, April 30, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it will present at the ThinkEquity Conference on May 2, 2019 at 2:30 pm ET at the Lotus Room of the Mandarin Oriental Hotel in New York City. The ThinkEquity conference brings together companies in healthcare, technology, finance, and energy with institutional and accredited investors. ThinkEquity is a division of Fordham Financial Management, Inc.

  • Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis
    PR Newswire23 days ago

    Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis

    - LO2A eye drops met primary efficacy endpoint for DES in patients with moderate to severe CCh - LO2A safety confirmed in all measured parameters - $3.7 billion global DES treatment market expected to ...

  • Wize Pharma's CEO Noam Danenberg Increases Stake in Company
    PR Newswire28 days ago

    Wize Pharma's CEO Noam Danenberg Increases Stake in Company

    HOD HASHARON, Israel, April 24, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today the Company's Chief Executive Officer, Mr. Noam Danenberg, has increased his ownership of common stock in Wize Pharma to 1.66% of the Company's outstanding shares, and increased his beneficial ownership including common stock and other convertible securities to 7.70%.

  • Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer
    PR Newswire29 days ago

    Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer

    HOD HASHARON, Israel, April 23, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, is pleased to announce that Mr. Mark Sieczkarek has been appointed Chairman of Wize Pharma's Board of Directors, replacing Mr. Noam Danenberg, who will become the Company's Chief Executive Officer, effective April 23, 2019.

  • LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary
    PR Newswire2 months ago

    LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary

    Wize Pharma Pursuing LO2A In Same and Related Indications in Additional Geographies LO2A Receives Third Therapeutic Indication in EU Country HOD HASHARON, Israel, March 11, 2019 /PRNewswire/ --  Wize Pharma, ...

  • Cannabics Pharmaceuticals Closes Agreement With Wize Pharma
    PR Newswire3 months ago

    Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

    BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

  • Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
    PR Newswire3 months ago

    Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

    Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" ...

  • Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
    PR Newswire3 months ago

    Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

    BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Initially announced in a press release on June 29, 2018, the two companies have been advancing planning and have concluded, that subject to completing a mutually agreeable business plan and obtaining an expert opinion in order to identify a potential FDA route for ophthalmic therapy containing cannabinoids, each expected to occur within 30 days, that they are ready to form a joint venture (JV) company, for the purpose of researching, developing, and administering cannabinoid formulations to treat ophthalmic disorder indications.

  • Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
    PR Newswire3 months ago

    Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions

    HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions  with Cannabics Pharmaceuticals Inc. ("Cannabics") (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects. The agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids.  Upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics and Cannabics shall issue 2,263,944 shares of its common stock to Wize.  The agreement shall expire if the parties have not approved a business plan by June 30, 2019.

  • Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye
    PR Newswire4 months ago

    Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye

    Data shows statistically significant improvement after 3 months of treatment in both objective and subjective measures HOD HASHARON, Israel, Jan. 10, 2019 /PRNewswire/ -- Wize Pharma, Inc.  ("Wize ...

  • Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis
    PR Newswire6 months ago

    Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis

    HOD HASHARON, Israel, Nov. 20, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh).

  • Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement
    PR Newswire7 months ago

    Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement

    HOD HASHARON, Israel , Oct. 24, 2018 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment ...

  • Wize Pharma, Inc. Announces $4.45 Million Private Placement
    PR Newswire7 months ago

    Wize Pharma, Inc. Announces $4.45 Million Private Placement

    HOD HASHARON, Israel , Oct 23, 2018 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment ...

  • Wize Pharma Appoints Ellen Lubman to its Advisory Board
    PR Newswire8 months ago

    Wize Pharma Appoints Ellen Lubman to its Advisory Board

    HOD HASHARON, Israel, Sept. 12, 2018 /PRNewswire/ --  Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced the appointment of Ellen A. Lubman to its Advisory Board. Ms. Lubman, a biotech executive specializing in business development, asset acquisitions and strategic partnering, will serve as a strategic advisor to Wize's senior management and Board of Directors.

  • Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board
    PR Newswire10 months ago

    Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board

    HOD HASHARON, Israel, July 26, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) (the "Company" or "Wize"), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Dr. Penny Asbell, a leading key opinion leader in the treatment of dry eye syndrome has joined the Company's Advisory Board. As a principal investigator in countless clinical studies sponsored by the National Institute of Health's National Eye Institute and by industry sponsors, Dr. Asbell has participated in the development of pharmaceuticals that have included pivotal treatments for ocular conditions including dry eyes.

  • Wize Pharma Signs Distribution Agreement in China for LO2A
    PR Newswirelast year

    Wize Pharma Signs Distribution Agreement in China for LO2A

    HOD HASHARON, Israel, June 5, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has signed an exclusive distribution agreement with HPGC Medical Co., Ltd. (HPGC) for the distribution in China by HPGC of a formula known as LO2A, a drug developed for the treatment of dry eye syndrome (DES), and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjögren's syndrome (Sjögren's). HPGC is a division of Harbin Pharmaceutical Group Co. Ltd., one of China's largest healthcare companies with 20,000 employees and assets worth $2.9 billion.

  • Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
    PR Newswirelast year

    Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome

    The poster presentation titled, "The anti-inflammatory effect of isotonic glycerol in Sjögren's syndrome-related dry eye" was delivered by Dr. Huba J. Kiss and presented findings from a study conducted by him at the Department of Ophthalmology, Semmelweis University, in Budapest, Hungary.